Clinical trials: Intravenous Infusions
Heart Failure
A Double-Blind Pharmacokinetic Interaction Study Evaluating the Effect of a Single IV Infusion of GGF2 or Placebo on Midazolam Pharmacokinetics in Patients With Heart Failure
The study will examine midazolam pharmacokinetics following single dose administration of 3 planned dose levels of GGF2 .
- Trial name
- NCT01944683
- Testing
- GGF2, Midazolam
- Where
- 8 sites in United States
- Volunteers
- 22 people
- Sponsor
- Acorda Therapeutics
Healthy
A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of CR6261 in Japanese Healthy Participants
The purpose of the study is to assess the safety, pharmacokinetics (what the body does to the drug) and immunogenicity (ability of a particular substance to provoke an immune response in the human body) of CR6261 in Japanese…
- Trial name
- NCT02016066
- Testing
- CR6261
- Where
- Japan
- Volunteers
- healthy volunteers welcome
- Sponsor
- Janssen Pharmaceutical K.K.
Influenza, Human
Pharmacokinetics of Zanamivir After Single and Repeated Dose Infusion Administration in Healthy Chinese Adults
Zanamivir is a potent and highly selective inhibitor of the influenza virus neuraminidase. Intravenous (IV) zanamivir is being developed for treatment of hospitalized patients with influenza, especially for those patients who may…
- Trial name
- NCT02377401
- Testing
- Zanamivir
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Volunteers
Measure Exposure Of Tanezumab In Healthy Volunteers When Administering The Drug Subcutaneously
The hypothesis of this study is that subcutaneous administration of tanezumab results in lower drug exposure compared to intravenous administration of tanezumab.
- Trial name
- NCT00788294
- Testing
- tanezumab
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Pfizer
Volunteers, Healthy
A Study to Evaluate Plasma Gelsolin in Healthy Volunteers
Study BTI-101 is a Phase 1, randomized, double-blind, placebo-controlled, dose escalation, parallel design study to evaluate the safety, tolerability, and pharmacokinetics of IV rhu-pGSN or saline placebo administered as 5 doses…
- Trial name
- NCT05789745
- Testing
- Recombinant human plasma gelsolin
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- BioAegis Therapeutics Inc.
Heart Failure, Congestive, Heart Decompensation
A Study of Two Doses of Intravenous NATRECOR hBNP (Nesiritide) in Patients With Worsening Congestive Heart Failure Who Have Difficulty Breathing at Rest
The purpose of this study is to assess the safety and efficacy of two doses of intravenous NATRECOR® hBNP (a recombinant form of the natural human peptide normally secreted by the heart) versus placebo in the treatment of…
- Trial name
- NCT00288730
- Testing
- nesiritide
- Volunteers
- 127 people
- Sponsor
- Scios, Inc.
Skeletal Muscle Relaxation
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS3797 in Healthy Subjects
This is a single-center, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS3797 in Chinese adults.
- Trial name
- NCT05701826
- Testing
- HRS3797
- Where
- China
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Advanced Solid Tumors
First in Human Trial of TAS266 in Patients With Advanced Solid Tumors
This study will assess safety, tolerability, maximum tolerated dose or recommended dose for expansion of TAS266 administered by IV infusion to patients with advanced solid tumors.
- Trial name
- NCT01529307
- Testing
- TAS266
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Novartis Pharmaceuticals
Preemptive Therapy of Patients At Risk for Acute Kidney Injury Following Cardiac Surgery
Phase 1B/2 Clinical Trial Assessing the Safety, Tolerability and Preliminary Efficacy of the Intravenous Administration of Allogeneic Placental Mesenchymal Cells for the Preemptive Treatment of Patients At Risk for Acute Kidney Injury Following Cardiac Surgery
This clinical trial is designed to evaluate KELI-101 versus placebo for the prevention of acute kidney disease leading to chronic kidney disease in subjects at high risk for acute kidney injury following cardiac surgery.
- Trial name
- MesAKI (NCT06678399)
- Testing
- KELI-101
- Volunteers
- 91 people
- Sponsor
- Kelifarma
Atrial Fibrillation
A Study of IV HBI-3000 for the Conversion Recent Onset Atrial Fibrillation (AF)
This Phase 2 study is a two-stage, serial cohort dose escalation and expansion study of a single 30-minute (IV) infusion of HBI-3000 for the conversion of patients with recent-onset atrial fibrillation (AF).
- Trial name
- NCT04680026
- Testing
- HBI-3000
- Where
- 14 sites in United States, Bosnia and Herzegovina and 3 more
- Volunteers
- 150 people
- Sponsor
- HUYABIO International, LLC.
Healthy
Single Ascending Dose Trial to Evaluate the Safety, Tolerability, PK, and PD of MT1002 for Injection
This is an open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single dose of MT1002 for injection following intravenous bolus/infusion ascending dose administration.
- Trial name
- NCT04116840
- Testing
- MT1002 for injection
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Malignant Solid Tumors
One Trial of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody in Patients With Malignant Solid Tumors
This is an open-label, dose-escalation and dose-expansion Phase I /II clinical study divided into Phase I and Phase II to evaluate the safety and tolerability of JCXH-211 combined with anti-PD-1 antibody in patients with…
- Trial name
- NCT06781125
- Testing
- JCXH-211 Intratumoral Injection Combined with Anti-PD-1 Antibody IV infusion
- Volunteers
- 72 people
- Sponsor
- Immorna Biotherapeutics, Inc.
Unspecified Adult Solid Tumor, Protocol Specific
Phenoxodiol in Treating Patients With Refractory Solid Tumors
RATIONALE: Phenoxodiol may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase I trial to study the effectiveness of phenoxodiol in treating patients who have refractory solid…
- Trial name
- NCT00022295
- Testing
- idronoxil
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Kazia Therapeutics Limited
Type 2 Diabetes
Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes
This study is being conducted to assess the overall safety and tolerability of a single intravenous infusion of three doses of Mesenchymal Precursor Cells versus Placebo in subjects with Type 2 Diabetes inadequately controlled on…
- Trial name
- NCT01576328
- Testing
- Mesenchymal Precursor Cells (MPCs)
- Where
- 18 sites in United States
- Volunteers
- 61 people
- Sponsor
- Mesoblast, Ltd.
Prostate Cancer
AGS-1C4D4 in Patients With Advanced Hormone Refractory Prostate Cancer
The present study will investigate the safety, tolerability and spectrum of side effects of AGS-1C4D4. As such, this study will characterize the dose limiting toxicities (DLT) and potentially the maximum tolerated dose (MTD) of…
- Trial name
- NCT00519233
- Testing
- AGS-1C4D4
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Astellas Pharma Inc
Generalized Myasthenia Gravis
Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis
The purpose of this study is to investigate the Pharmacodynamics (PD), Pharmacokinetics (PK), safety, tolerability, immunogenicity, and clinical efficacy of efgartigimod coformulated with recombinant human hyaluronidase PH20…
- Trial name
- ADAPTsc (NCT04735432)
- Testing
- efgartigimod PH20 SC, efgartigimod IV
- Where
- 47 sites in United States, Belgium and 9 more
- Volunteers
- 110 people
- Sponsor
- argenx
Castration Resistant Metastatic Prostate Cancer, Prostate Cancer
A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer
This is a Phase 1b, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of [64Cu]Cu-AKY-2519 and/or [225Ac]Ac-AKY-2519, as well as the preliminary anti-tumor activity of…
- Conditions
- Castration Resistant Metastatic Prostate Cancer, Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer), mCRPC
- Trial name
- BActinium-1 (NCT07581184)
- Testing
- [225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging)
- Where
- 8 sites in United States
- Volunteers
- 138 people
- Sponsor
- Aktis Oncology, Inc.
Healthy
The Safety and Tolerability of STSA-1005 Following Intravenous Infusion in Healthy Subjects
This was a single ascending dose, randomized, double-blind study assessing the safety, tolerability and pharmacokinetics of STSA-1005 in healthy participants.
- Trial name
- NCT05085197
- Testing
- STSA-1005 injection
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Staidson Biopharma Inc.
Melanoma
Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma
The purpose of this study is to determine the safety and tolerability of intravenous administration of a tetravalent RNA-lipoplex cancer vaccine targeting four tumor-associated antigens in patients with advanced melanoma.
- Trial name
- Lipo-MERIT (NCT02410733)
- Testing
- Lipo-MERIT
- Where
- 4 sites in Germany
- Volunteers
- 119 people
- Sponsor
- BioNTech SE
West Nile Virus
A Trial to Evaluate the Safety of a Single Intravenous Infusion of MGAWN1 in Healthy Adults
The primary purpose of this phase 1, double-blind, cohort study is to evaluate the safety, tolerability, and pharmacokinetics of escalating doses of MGAWN1 administered as a single intravenous (IV) infusion to healthy adults.
- Trial name
- NCT00515385
- Testing
- MGAWN1
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- MacroGenics